Continued growth in the licensing business and in our product portfolio
Second quarter (April-June 2022)
- Revenues amounted to
SEK 59.9 (46.0) million, an increase of 30%. Adjusted for currency, revenues increased by 13%. -
EBITDA amounted to
SEK -3.8 (1.8) million, with an EBITDA margin of -6.4% (4.0). -
Operating profit/loss amounted to
SEK -14.8 (-10.0) million, a decrease ofSEK -4.9 million . -
Net profit/loss for the period amounted to
SEK -13.7 (-12.0) million. -
Losses per share amounted to
SEK -0.39 (-0.36). -
Cash flow from operating activities amounted to
SEK -1.9 (5.5) million, corresponding toSEK -0.05 (0.16) per share.
First half year (January-June 2022)
- Revenues amounted to
SEK 115.1 (87.8) million, an increase of 31%. Adjusted for currency, revenues increased by 13%. -
EBITDA amounted to
SEK -7.8 (3.7) million, with an EBITDA margin of -6.8% (4.3). -
Operating profit/loss amounted to
SEK -31.4 (-19.7) million, a decrease ofSEK -11.7 million . -
Net profit/loss for the period amounted to
SEK -30.2 (-22.6) million. -
Losses per share amounted to
SEK -0.86 (-0.67). -
Cash flow from operating activities amounted to
SEK -13.8 (4.6) million, corresponding toSEK -0.39 (0.14) per share.
Key events during the second quarter
Bactiguard announced in April that the company has entered a global development agreement withDentsply Sirona in the dental area.-
Senior executives and key personnel in
Bactiguard have acquired call options issued by the main owners, comprising 4 percent of all B-shares inBactiguard .
Key events after the end of the quarter
- The third-generation patent for
Bactiguard technology is intended to be granted by theEuropean Patent Office (EPO).
Impact of macro events on the company
Covid-19 continues to affect global trade, including shutdowns in
CEO comments the second quarter
Continued growth in the licensing business and in our product portfolio
Revenue for the quarter was
We now have three key drivers for license growth
The license business grows with 15 percent in the quarter, including currency effects which is clear evidence of the value of the unique
Licensing revenues from BD was strong this quarter, and the previous quarter. BD is one of the largest global medical technology companies and has the exclusive right to sell our urinary catheter with the effective
Our cooperation with
Continued growth in our BIP-portfolio of Bactiguard Catheters and Wound care
We continue to see an increasing demand for our catheters with
Investments for profitable growth
We continue to strengthen our organization to create a strong platform for accelerated profitable growth. Focus is on license product development, regulatory approvals, patent protection, higher production capacity and an expansion of the license and sales organizations.
Outlook
The demand for our technology and products is driven by the need to reduce infections, a growing problem throughout the world. Infections causes lower quality of life for patients and increased healthcare costs, and in the worst case the patient dies. A rise in the number of infections is causing an increase in the use of antibiotics which, in turn, causes antimicrobial resistance - an increasing global problem - making infection prevention even more important. With our offering we can prevent infections.
The progress we have made during the quarter is a confirmation of the strength of our offering and reinforce us in our ambition to continue to develop our technology and find new application areas. The fact that the
To achieve our long-term growth and profitability targets by 2026, we will, as communicated when the goals were presented, strengthen the organization and initiate a number of growth measures. As a result, the operating margin in 2022 and 2023 will be affected, even if the company's sales are continuously growing. We are early in our growth journey, and we are following our plan.
CEO
The interim report for
This information is information that
For further information, please contact:
Carin Jakobson CFO, mobile: +46 70 965 16 65
Presentation of Q2
An audiocast for investors, analysts and media will be held at
To participate in the audiocast, use this link:
www.bactiguard.com/Q2-2022
To participate only by conference call, dial:
SE: +46850558358,
About
The
Read more about
https://news.cision.com/bactiguard-holding-ab--publ-/r/interim-report-for-q2-2022,c3601048
https://mb.cision.com/Main/9686/3601048/1604247.pdf
https://mb.cision.com/Public/9686/3601048/a1302f72934f653b.pdf
(c) 2022 Cision. All rights reserved., source